Vernakalant--a new drug for pharmacological conversion of atrial fibrillation

Vernakalant is a new antiarrhythmic drug which is used for rapid conversion of atrial fibrillation. The drug is a relatively atrium-selective K' and Na+ channel blocker, prolonging the atrial refractory period. Clinical trials showed conversion rates of about 50% which is comparable to other antiarrhythmic drugs. Further trials will show if vernakalant is less pro-arrythmogenic than its competitors.